23andMe Investor Presentation Deck
80%
Customers receive a
report with a
meaningful genetic
variant
18,000+
Customers with an
increased risk for Chronic
Kidney Disease
8,000+ 12,000+
Customers with
a tested BRCA1 /
BRCA2 variant
Customers with
Hypercholesterolemia
(FH) variants
Note: Estimates based on prevalence of variants in 23andMe's Database as of June 30, 2022.
Providing Customers
With Key, Actionable
Insights
"Like me, there are many women who have slipped through the
cracks of our current medical screening system, either because they
don't have a family history of breast or ovarian cancer. Or they do
not know that they have Ashkenazi Jewish ancestry. In my case,
even though I know I have Ashkenazi ancestry, that wasn't enough
to prompt my doctor to consider screening. So there are many
women walking around with this risk, who, like me, would have never
known of their own risk but for this test from 23andMe."
23andMe customer who discovered she had a BRCA1 mutationView entire presentation